Customize
Quick Links
Past Events

Accreditation/
Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this live activity for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Acknowledgment of Commercial Support

This activity is supported by an educational grant from Juno Therapeutics.




Friday Satellite Symposium on The Emergence of CAR-T Cell Therapy for Hematologic Malignancies: Moving From Bench to Bedside, preceding the 58th ASH Annual Meeting and Exposition.

About
Accreditation
Privacy Policy
Terms & Conditions
Executive Board
Journal
Faculty Portal
Contact
Facebook
Twitter
LinkedIn
Google +
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
Physicians’ Education Resource ®, LLC.
All rights reserved.

The Emergence of CAR-T Cell Therapy for Hematologic Malignancies: Moving From Bench to Bedside

The Emergence of CAR-T Cell Therapy for Hematologic Malignancies: Moving From Bench to Bedside


Friday, December 2, 2016

Registration:
1:00 PM

Lunch and Satellite Symposia: 1:30 PM - 4:30 PM

Marriott Marquis San Diego Marina
Grand Ballroom 8-9
San Diego, CA


Overview

The Emergence of CAR-T Cell Therapy for Hematologic Malignancies: Moving from Bench to Bedside is a live symposium to be held in conjunction with the Annual Meeting in San Diego. The use of chimeric antigen receptor (CAR)-modified T-cell therapies is being investigated for use in a number of hematologic malignancies. Promising early phase clinical trial results have been reported in acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL). There is a major educational need for initiatives that update clinicians on the mechanism of action of CAR-T therapies, the latest clinical trial results from completed and ongoing investigations, and methods to proactively plan for and mitigate treatment-related toxicities. The timing of the San Diego meeting, in conjunction with the late-stage clinical development of these novel approaches to treat cancer, makes the meeting the perfect venue for a program dedicated to this important topic. This program is intended to meet the educational needs of the busy clinician who manages some of the most difficult-to-treat hematologic malignancies.  

Please join us Friday, December 2nd, 2016, from 12:30 PM to 4:30 PM for this not-to-be-missed CME -Certified activity on one of the most exciting novel approaches being developed in the field!! 

Key topics on the agenda include:

  • The evolution of CAR-T cell technology
  • The potential for CAR-T cells in clinical practice for hematologic malignancies, including ALL and other hematologic malignancies
  • Safety and toxicity management of CAR-T cell technology in pediatric and adult patients

Renowned experts with specific practical expertise with the application of these therapies will discuss the aforementioned topics. They will also discuss how to coordinate care between academic centers and community practices in the context of patient selection, the evolving role of transplant, and the role of the community practitioner during and after treatment with these novel approaches to care. 

This is an educational activity not to be missed in San Diego on the first Friday in December!! 

Why Should I Attend?

Renowned experts with specific practical expertise with the application of these therapies will discuss the aforementioned topics. They will also discuss how to coordinate care between academic centers and community practices in the context of patient selection, the evolving role of transplant, and the role of the community practitioner during and after treatment with these novel approaches to care. 

Target Audience

These activities are intended for medical oncologists, hematologists, and other oncology healthcare professionals interested in the latest advances in the use of CAR T-cell therapy for patients with hematologic malignancies. Fellows, researchers, nurses, nurse practitioners, physician assistants, and other healthcare professionals interested in the treatment of patients with hematologic malignancies are also invited to attend.

Learning Objectives

At the end of this activity, you should be better prepared to:

  • Describe the structure and function of the CAR and the mechanism of action of CAR-T cells in lymphoma
  • Review clinical trial evidence in acute lymphoblastic leukemia (ALL) and describe where CAR-T cell therapies might fit in the treatment landscape
  • Review clinical trial evidence in other lymphoid malignancies and describe where CAR-T cell therapy might fit in the treatment landscape
  • Identify and discuss the management of toxicities of CAR-T cell therapies

Program Chair

Stephen J. Forman, MD, FACP
Program Leader of the Hematologic Malignancies Program
City Of Hope
Duarte, CA

 







Become a Member

Forgot Password?
Filter By